Modalis Therapeutics

Modalis Therapeutics Corporation is developing precision genetic medicines through epigenetic gene modulation. Modalis is advancing treatments for orphan genetic diseases using its proprietary CRISPR-GNDM technology, which enables locus-specific regulation of gene expression or histone modification without the need for double-strand DNA cuts, gene editing, or base editing. Modalis is headquartered in Tokyo, with laboratories and R&D facilities in Cambridge.